Document is current
Any future updates will be listed below
-
Authors
Klein, Sebastian https://orcid.org/0000-0002-2188-9377
Wuerdemann, Nora
Demers, Imke https://orcid.org/0000-0001-9531-8414
Kopp, Christopher
Quantius, Jennifer
Charpentier, Arthur
Tolkach, Yuri
Brinker, Klaus
Sharma, Shachi Jenny
George, Julie
Hess, Jochen
Stögbauer, Fabian https://orcid.org/0000-0002-8897-5165
Lacko, Martin https://orcid.org/0000-0003-2868-4822
Struijlaart, Marijn
van den Hout, Mari F.C.M.
Wagner, Steffen https://orcid.org/0000-0003-0873-1601
Wittekindt, Claus
Langer, Christine
Arens, Christoph https://orcid.org/0000-0001-8072-1438
Buettner, Reinhard https://orcid.org/0000-0001-8806-4786
Quaas, Alexander
Reinhardt, Hans Christian
Speel, Ernst-Jan
Klussmann, Jens Peter
- License Information
-
More Information
Article History
Received: 31 August 2022
Accepted: 10 August 2023
First Online: 19 August 2023
Competing interests
: J.H. received consulting and lecture fees from BMS, also received research funding from CureVac. R.B. received consulting and lecture fees from AbbVie, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Illumina, Lilly, Merck-Serono, MSD, Novartis, Qiagen, Pfizer, Roche, Targos MP Inc. R.B. is Co-Founder and Scientific Advisor for Targos Mol. Pathology Inc and member of the Directory Board Gnothis Inc. H.C.R. received consulting and lecture fees from Novartis, Abbvie, AstraZeneca, Vertex and Merck. H.C.R. received research funding from AstraZeneca and Gilead Pharmaceuticals. HCR is a co-founder of CDL Therapeutics GmbH. The remaining authors declare no competing interests.
